Noel A Vest1, Sterling McPherson2, G Leonard Burns3, Sarah Tragesser4. 1. Washington State University, Department of Psychology, Pullman, WA 99164-4820, United States. Electronic address: noelvest@stanford.edu. 2. Washington State University, Elson S. Floyd College of Medicine, Analytics & Psychopharmacology Laboratory (APPL), 412 E. Spokane Falls Blvd. Spokane, WA 99202-2131, United States. Electronic address: sterling.mcpherson@wsu.edu. 3. Washington State University, Department of Psychology, Pullman, WA 99164-4820, United States. Electronic address: glburns@wsu.edu. 4. Washington State University, Department of Psychology, Pullman, WA 99164-4820, United States. Electronic address: sarah_tragesser@wsu.edu.
Abstract
BACKGROUND: Relapse is common in treatment for opioid use disorders (OUDs). Pain and depression often co-occur during OUD treatment, yet little is known about how they influence relapse among patients with a primary diagnosis of prescription opioid use disorder (POUD). Advanced statistical analyses that can simultaneously model these two conditions may lead to targeted clinical interventions. METHOD: The objective of this study was to utilize a discrete survival analysis with a growth mixture model to test time to prescription opioid relapse, predicted by parallel growth trajectories of depression and pain, in a clinical sample of patients in buprenorphine/naloxone treatment. The latent class analysis characterized heterogeneity with data collected from the National Institute of Drug Abuse Clinical Trials Network project (CTN-0030). RESULTS: Results suggested that a 4-class solution was the most parsimonious based on global fit indices and clinical relevance. The 4 classes identified were: 1) low relapse, 2) high depression and moderate pain, 3) high pain, and 4) high relapse. Odds ratios for time-to-first use indicated no statistically significant difference in time to relapse between the high pain and the high depression classes, but all other classes differed significantly. CONCLUSION: This is the first longitudinal study to characterize the influence of pain, depression, and relapse in patients receiving buprenorphine and naloxone treatment. These results emphasize the need to monitor the influence of pain and depression during stabilization on buprenorphine and naloxone. Future work may identify appropriate interventions that can be introduced to extend time-to-first prescription opioid use among patients.
BACKGROUND: Relapse is common in treatment for opioid use disorders (OUDs). Pain and depression often co-occur during OUD treatment, yet little is known about how they influence relapse among patients with a primary diagnosis of prescription opioid use disorder (POUD). Advanced statistical analyses that can simultaneously model these two conditions may lead to targeted clinical interventions. METHOD: The objective of this study was to utilize a discrete survival analysis with a growth mixture model to test time to prescription opioid relapse, predicted by parallel growth trajectories of depression and pain, in a clinical sample of patients in buprenorphine/naloxone treatment. The latent class analysis characterized heterogeneity with data collected from the National Institute of Drug Abuse Clinical Trials Network project (CTN-0030). RESULTS: Results suggested that a 4-class solution was the most parsimonious based on global fit indices and clinical relevance. The 4 classes identified were: 1) low relapse, 2) high depression and moderate pain, 3) high pain, and 4) high relapse. Odds ratios for time-to-first use indicated no statistically significant difference in time to relapse between the high pain and the high depression classes, but all other classes differed significantly. CONCLUSION: This is the first longitudinal study to characterize the influence of pain, depression, and relapse in patients receiving buprenorphine and naloxone treatment. These results emphasize the need to monitor the influence of pain and depression during stabilization on buprenorphine and naloxone. Future work may identify appropriate interventions that can be introduced to extend time-to-first prescription opioid use among patients.
Authors: Kevin W Chen; Annie N Banducci; Leila Guller; Richard J Macatee; Anna Lavelle; Stacey B Daughters; C W Lejuez Journal: Drug Alcohol Depend Date: 2011-04-22 Impact factor: 4.492
Authors: Stacey C Sigmon; Kelly E Dunn; Kathryn Saulsgiver; Mollie E Patrick; Gary J Badger; Sarah H Heil; John R Brooklyn; Stephen T Higgins Journal: JAMA Psychiatry Date: 2013-12 Impact factor: 21.596
Authors: Michael D Stein; Debra S Herman; Genie L Bailey; John Straus; Bradley J Anderson; Lisa A Uebelacker; Risa B Weisberg Journal: J Gen Intern Med Date: 2015-02-13 Impact factor: 5.128
Authors: Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison Journal: J Pain Symptom Manage Date: 2004-09 Impact factor: 3.612
Authors: Caleb J Banta-Green; Joseph O Merrill; Suzanne R Doyle; Denise M Boudreau; Donald A Calsyn Journal: Drug Alcohol Depend Date: 2009-05-26 Impact factor: 4.492
Authors: Jennifer D Ellis; Jill A Rabinowitz; Jonathan Wells; Fangyu Liu; Patrick H Finan; Michael D Stein; Denis G Antoine Ii; Gregory J Hobelmann; Andrew S Huhn Journal: J Affect Disord Date: 2021-12-04 Impact factor: 4.839
Authors: Erin S Rogers; Elizabeth Vargas; Christina N Wysota; Scott E Sherman Journal: Int J Environ Res Public Health Date: 2022-02-26 Impact factor: 3.390